Adeona Pharmaceuticals, Inc. (Adeona) is a development-stage, specialty pharmaceutical company that is developing late-stage drug candidates for the treatment of opththalmic, neurologic and autoimmune diseases. The Company is a specialty pharmaceutical company that is preparing to commercialize a series of products for the prevention and treatment of degenerative conditions that the Company involve subclinical zinc deficiency and/or chronic copper toxicity. The Company conditions are highly prevalent and under-recognized in the aging population and that they may contribute to the progression of dry age-related macular degeneration (dry AMD), Alzheimer’s disease (AD), and mild cognitive impairment (MCI). Its product candidate brands, Zinthionein and EyeDaily with Zinthionein, are expected to be products that contain ingredients (such as, zinc monocysteine complex). In July 2009, Adeona completed the acquisition of HartLab LLC, an independent clinical laboratory.